WTO Quantitative Restrictions

Singapore #3793 (v.3)

Base data

Notified in
Version validity
01/10/2020 - present
Current active version v.3
Reporting member
Singapore
In force from
End date
In force
General description
Non-automatic licence for the import of Cell and Tissue Therapy Products and Chinese proprietary medicines
National legal basis
Medicines Act; 1975
Administrative mechanism
While the controls of chemical and biologic drugs have been transferred from the Medicines Act to the Health Products Act from 1 Nov 2016, cell and tissue –based products and CPMs will continue to be regulated under the Medicines Act for now.

More information can be found at: https://www.hsa.gov.sg/.

Administered by HSA.
Responsible entities
Health Sciences Authority
HS version
HS 2017
Referenced WTO document symbol

Meta data

WTO justifications

XX:(b) - (b) necessary to protect human, animal or plant life or health;

GATT 1994 (GATT 1947 provisions)

Reported as: Article XX(b) of the GATT
Non-WTO commitments
Affected partners
Non-affected partners

Measures

Reported restrictions
NAL
Symbol
NAL

Tariff lines
NA
Cell and tissue therapy products refer to cellular and tissue based medicinal products. Chinese prop...